跳至主要内容
临床试验/ACTRN12607000223437
ACTRN12607000223437撤回1 期

A single centre open-label pilot study to evaluate the tolerability and safety of the Family C synthetic thermoplastic block copolymer implant as a clinically acceptable dermal filler material in healthy volunteers.

COSMETREND PTY LTD0 个研究点目标入组 8 人开始时间: 2007年4月27日最近更新:
适应症

试验速览

阶段
1 期
状态
撤回
发起方
入组人数
8

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • 1. In generally good health2. Participants willing and able to comply with the requirements of the study3. Participants willing and able to comply with the follow-up requirements4. Participants willing and able to give informed consent5. Females must be post-menopausal, surgically sterile or willing to use a medically acceptable form of birth control during the study. Males must be willing to use a medically acceptable form of birth control during the study.

排除标准

  • 1. Participants who are pregnant, nursing or intend to become pregnant during the study period2. Participants who were or are currently being treated with any systemic immunosuppressive therapy including but not limited to chemotherapy agents or corticosteroids within the past 3 months. The use of stable doses of inhaled corticosteroids is acceptable.3. Participants who were or are currently being treated with any topical Over The Counter (OTC) drug or prescription therapy on their torso within the past 3 months.4. Participants with skin findings or disease in the proposed implant area that could confound the interpretation of the reactivity of the implant sites.5. Participants with a history indicative of abnormal immune function (e.g. auto-immune diseases, HIV, cancer [other than non-melanoma skin cancer], etc.)6. Participants with known sensitivity to any of the Test Article materials.7. Participants with severe allergies manifested by a history of anaphylaxis.8. Participant is currently enrolled in an investigational drug or device study. 9. Participant has received an investigational drug or treatment with an investigational device within 30 days prior to entering this study.

研究者

发起方
COSMETREND PTY LTD

相似试验

招募中
1 期
Pentosan Polysulfate Sodium (PPS) in subjects with mucopolysaccharidosis type I (MPS I)Mucopolysaccharidosis type I (MPS I)Metabolic and Endocrine - Metabolic disordersHuman Genetics and Inherited Disorders - Other human genetics and inherited disorders
ACTRN12620000823976Paradigm Biopharmaceuticals Pty Ltd10
进行中(未招募)
1 期
A pilot study to assess the efficacy and safety of CBD oral solution in addition to standard treatment for pediatric subjects with Developmental and Epileptic EncephalopathyDevelopmental and Epileptic Encephalopathy (DEE)MedDRA version: 20.0Level: PTClassification code 10077380Term: Epileptic encephalopathySystem Organ Class: 10029205 - Nervous system disorders
EUCTR2019-001633-14-ITIRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA20
已完成
1 期
A single center, open-labeled, pilot study to evaluate the safety and efficacy of cardiac cycle-synchronized electrical lower limb muscle stimulation therapy for cardiovascular diseaseatent heart failure (NYHA class: II-III), ischemic heart disease (CCS class: II-III), peripheral artery disease (Fontaine class: II-IV), pulmonary artery hypertension (WHO class: II-III), and healthy adult
JPRN-UMIN000026841Kurume University School of Medicine, Division of Cardiovascular Medicine, Department of Internal Medicine30
尚未招募
1 期
Biocompatible & Biodegradable Polymeric Skin Grafts for Wounds
CTRI/2020/11/029284SASTRA Deemed University
招募中
1 期
A pilot single center, open label trial to assess the impact of doxycycline postexposure prophylaxis on antimicrobial resistance (SafeDoxyPEP trial)Bacterial sexually transmittable diseases (chlamydia, gonorrhea, syphilis)
CTIS2023-507137-24-00Institute Of Tropical Medicine78